Summary of opinion: Mhyosphere PCV ID, 06/11/2025 Positive
Submitted by Anonymous (not verified) on 7 November 2025 - 14:00
Summary of opinion: Mhyosphere PCV ID, 06/11/2025 Positive
Withdrawn application: Dupixent, 18/02/2025
Submitted by Anonymous (not verified) on 7 November 2025 - 14:00
Withdrawn application: Dupixent, 18/02/2025
Personalised medicine in oncology
Submitted by Anonymous (not verified) on 7 November 2025 - 13:09
Personalised medicine in oncology
Cancer medicines
Submitted by Anonymous (not verified) on 7 November 2025 - 13:09
Cancer medicines
CVMP recommendations on limited market classification and eligibility for authorisation under Article 23
Submitted by Anonymous (not verified) on 7 November 2025 - 13:08
CVMP recommendations on limited market classification and eligibility for authorisation under Article 23
Release notes - production release version 1.7.2541 - 7 November 2025 - Veterinary Medicinal Products Regulation: Union Product Database
Submitted by Anonymous (not verified) on 7 November 2025 - 12:34
Release notes - production release version 1.7.2541 - 7 November 2025 - Veterinary Medicinal Products Regulation: Union Product Database
Clinical Trial Information System (CTIS) - Sponsor handbook
Submitted by Anonymous (not verified) on 7 November 2025 - 12:20
Clinical Trial Information System (CTIS) - Sponsor handbook
Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Date of authorisation: 19/01/2006, Revision: 41, Status: Authorised
Submitted by Anonymous (not verified) on 7 November 2025 - 12:00
Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Date of authorisation: 19/01/2006, Revision: 41, Status: Authorised
Human medicines European public assessment report (EPAR): Zepatier, elbasvir,grazoprevir, Date of authorisation: 22/07/2016, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 7 November 2025 - 11:35
Human medicines European public assessment report (EPAR): Zepatier, elbasvir,grazoprevir, Date of authorisation: 22/07/2016, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 7 November 2025 - 11:11
Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 1, Status: Authorised